menu search

ATNM / Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy

Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy
Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has potential beyond market expectations. The main pipeline update is the presentation of findings in patients with TP53 mutation, showing improved overall survival with Iomab-B. Actinium Pharmaceuticals has a relatively stable position with $83 million in cash and 6 more quarters of cash on hand, but may need to tie a BLA submission with a public offering. Read More
Posted: Nov 3 2023, 18:08
Author Name: Seeking Alpha
Views: 030110

ATNM News  

Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy

By Seeking Alpha
November 3, 2023

Actinium Pharmaceuticals: The Trickle Down Continues, And I Maintain A Buy

Actinium Pharmaceuticals continues to make progress with their radiolabelled CD45 antibody Iomab-B, which has potential beyond market expectations. Th more_horizontal

Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?

By Seeking Alpha
September 15, 2023

Actinium Pharmaceuticals Trickling Down Through 2023: Are They Flying Under The Radar?

Actinium is making radiolabeled antibodies for use in hematologic cancers. Previously reported phase 3 trial results give a strong indicator of succes more_horizontal

Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth

By Investors Business Daily
February 24, 2023

Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth

Actinium has lofty ambitions to change the landscape of leukemia treatment. But ATNM stock cratered this week on final-phase test results. more_horizontal

Actinium Pharmaceuticals: Prep For February

By Seeking Alpha
January 10, 2023

Actinium Pharmaceuticals: Prep For February

Actinium Pharmaceuticals is delivering the goods on a deep pipeline of therapeutics. It has deepened its bench with experienced operators. more_horizontal

Actinium (ATNM) Up on Commercialization Deal With Immedica

By Zacks Investment Research
April 13, 2022

Actinium (ATNM) Up on Commercialization Deal With Immedica

Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Euro more_horizontal

Why Actinium Pharmaceuticals Stock Is Surging

By Benzinga
April 12, 2022

Why Actinium Pharmaceuticals Stock Is Surging

Actinium Pharmaceuticals Inc (AMEX:ATNM) shares are trading higher Tuesday morning after the company announced it entered into a license and supply ag more_horizontal


Search within

Pages Search Results: